Published in Public Health Rep on June 01, 1998
Injecting Drug Use Community Intervention Trial | NCT01108614
HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health (2000) 2.74
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health (2005) 2.62
Black-white disparities in HIV/AIDS: the role of drug policy and the corrections system. J Health Care Poor Underserved (2005) 2.07
Prevention and treatment of hepatitis C in injection drug users. Hepatology (2002) 1.88
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2006) 1.81
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health (2000) 1.78
HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health (2000) 1.74
HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open (2012) 1.49
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. Lancet HIV (2015) 1.48
Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs (2009) 1.42
Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep (2007) 1.29
Managing la malilla: Exploring drug treatment experiences among injection drug users in Tijuana, Mexico, and their implications for drug law reform. Int J Drug Policy (2010) 1.24
HIV testing in correctional agencies and community treatment programs: the impact of internal organizational structure. J Subst Abuse Treat (2007) 1.21
The urgent need for HIV and hepatitis prevention in drug treatment programs in Hungary. AIDS Educ Prev (2004) 1.20
Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends. J Urban Health (2008) 1.13
Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse (2010) 1.07
Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open (2015) 0.98
Individual and social factors associated with participation in treatment programs for drug users. Subst Use Misuse (2008) 0.96
Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care. J Addict Med (2010) 0.94
Redefining retention: recovery from the patient's perspective. J Psychoactive Drugs (2011) 0.91
Ethnic differences in HIV risk behaviors among methadone-maintained women receiving contingency management for cocaine use disorders. Drug Alcohol Depend (2008) 0.89
The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls. BMC Public Health (2010) 0.87
Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective study. Harm Reduct J (2013) 0.86
Trends in the AIDS epidemic among New York City's injection drug users: localized or citywide? J Urban Health (2002) 0.83
Factors associated with methadone treatment duration: a Cox regression analysis. PLoS One (2015) 0.75
The Flawed Reliance on Randomized Controlled Trials in Studies of HIV Behavioral Prevention Interventions for People Who Inject Drugs and Other Populations. Subst Use Misuse (2015) 0.75
A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011. Int J Drug Policy (2016) 0.75
Is methadone a miracle cure or an alternative evil? West J Med (2000) 0.75
Substance abuse treatment as HIV prevention: more questions than answers. J Natl Med Assoc (2010) 0.75
Maintenance Treatment with Opium Tincture: A Preliminary Qualitative Study of the Factors Related to Treatment entry. Iran J Public Health (2014) 0.75
Patient-centered methadone treatment: a randomized clinical trial. Addiction (2016) 0.75
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA (1989) 6.68
The effects of psychosocial services in substance abuse treatment. JAMA (1993) 5.87
Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA (1989) 5.66
An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet (1997) 5.18
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1993) 5.08
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
Narcotic blockade. Arch Intern Med (1966) 3.80
Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS (1987) 3.78
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS (1994) 3.67
A synergism of plagues: "planned shrinkage," contagious housing destruction, and AIDS in the Bronx. Environ Res (1988) 3.63
Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA (1994) 3.41
Urban desertification, public health and public order: 'planned shrinkage', violent death, substance abuse and AIDS in the Bronx. Soc Sci Med (1990) 3.19
Prevalence of HIV infection among intravenous drug users in the United States. JAMA (1989) 3.13
Variations in methadone treatment practices. Results from a national study. JAMA (1992) 2.83
Implications of methadone maintenance for theories of narcotic addiction. JAMA (1988) 2.28
A method for estimating HIV transmission rates among female sex partners of male intravenous drug users. Am J Epidemiol (1991) 2.16
Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs. Am J Public Health (1995) 1.72
Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA (1989) 1.60
New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol (1991) 1.52
Drugs, sex and HIV: a mathematical model for New York City. Philos Trans R Soc Lond B Biol Sci (1991) 1.50
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health (1995) 1.40
Injection drug use and human immunodeficiency virus infection. Clin Infect Dis (1995) 1.31
Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Subst Use Misuse (1997) 1.26
Needle exchange use among a cohort of injecting drug users. AIDS (1996) 1.26
Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. J Subst Abuse Treat (1991) 1.20
Estimating population prevalence of human immunodeficiency virus infection in urban areas with high rates of intravenous drug use: a model of the Bronx in 1988. Am J Epidemiol (1989) 1.19
Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care (1994) 1.17
HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend (1994) 1.15
Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care (1992) 1.14
The demedicalization of methadone maintenance. J Psychoactive Drugs (1995) 1.10
The types of drugs used by HIV-infected injection drug users in a multistate surveillance project: implications for intervention. Am J Public Health (1994) 1.07
Longitudinal changes in injection behaviors in a cohort of injection drug users. Addiction (1994) 0.84
Decline in HIV-1 seroprevalence and low seroconversion rate among injecting drug users at a methadone maintenance program in New York City. J Psychoactive Drugs (1994) 0.83
Methadone maintenance counseling. Definition, principles, components. J Subst Abuse Treat (1995) 0.80
HIV, drugs, and ecology. Science (1989) 0.79
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 10.98
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis (2001) 5.43
Detection and treatment of hypertension at the work site. N Engl J Med (1975) 3.43
Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. JAMA (1989) 2.41
Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med (1992) 2.36
Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. J Infect Dis (2000) 2.25
High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA (1992) 2.19
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med (1993) 1.92
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS (1988) 1.75
Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS (2001) 1.68
Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug users. JAMA (1989) 1.63
A prospective study of HIV disease progression in female and male drug users. AIDS (1999) 1.54
Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med (1996) 1.47
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health (1995) 1.40
Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study. J Infect Dis (1997) 1.36
Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis (1998) 1.22
Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: an old infection? J Infect Dis (1991) 1.06
A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. Am J Public Health (1996) 1.02
Correlates of voluntary human immunodeficiency virus antibody testing reported by postpartum women. J Am Med Womens Assoc (1997) 1.01
Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J Leukoc Biol (2006) 0.99
Vitamin A deficiency and maternal-infant transmissions of HIV in two metropolitan areas in the United States. AIDS (1997) 0.96
Hypertension control among employed persons in New York City: 1973-75. Milbank Mem Fund Q Health Soc (1976) 0.95
Antibody to the human immunodeficiency virus in women seeking abortion in New York City. Ann Intern Med (1987) 0.94
Behavioral risks for HIV infection associated with HIV-testing decisions. AIDS Educ Prev (1996) 0.94
Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS (1999) 0.93
Pilot study of expedited HIV-1 testing of women in labor at an inner-city hospital in New York City. Am J Perinatol (2001) 0.92
In New York City, syringe laws and regulations deter physicians and pharmacists from prescribing and selling syringes to persons who may be injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.91
Body image in older men with or at-risk for HIV infection. AIDS Care (2007) 0.90
Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun (1999) 0.90
Body image in middle-aged HIV-infected and uninfected women. AIDS Care (2006) 0.89
Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women. HIV Med (2006) 0.88
A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis (2001) 0.86
Stress, coping, and attitudes toward HIV treatment in injecting drug users: a qualitative study. AIDS Educ Prev (1995) 0.86
A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients. Gen Hosp Psychiatry (1993) 0.81
Organization for long-term management of hypertension: the recruitment, training, and responsibilities of a health team. Bull N Y Acad Med (1976) 0.81
Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users. Epidemiology (1998) 0.81
The management of HIV disease in pregnancy. Baillieres Clin Obstet Gynaecol (1992) 0.80
The incidence of tuberculosis in drug users with small tuberculin reaction sizes. Int J Tuberc Lung Dis (2001) 0.79
Errors in reporting seropositivity for infection with human immunodeficiency virus (HIV) Ann Intern Med (1988) 0.79
Tampons as a self-administered collection method for the detection and quantification of genital HIV-1. AIDS (2001) 0.78
CD4+ lymphocyte level and rate of decline as predictors of AIDS in intravenous drug users with HIV infection. AIDS (1993) 0.78
Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J Epidemiol (1993) 0.77
Self-assessment of tuberculin skin test reactions by drug users with or at risk for human immunodeficiency virus infection. Int J Tuberc Lung Dis (1999) 0.75
A seroprevalence survey for human immunodeficiency virus antibody in mentally retarded adults. N Y State J Med (1990) 0.75
Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS (1994) 0.75
Association of baseline neuropsychological function and progression of illness over 4 years in HIV-seropositive individuals. Psychosomatics (1994) 0.75
Ulcerative colitis and hemophilia A. Mt Sinai J Med (1983) 0.75
Neurosyphilis in patients with human immunodeficiency virus infection. N Engl J Med (1995) 0.75
Heterosexual transmission of HIV infection in intravenous and non-intravenous drug-using populations. Arch AIDS Res (1991) 0.75